CD19 and neoplasm: CD28-4-1BBL-based CAR-T has shown safe and effective results in targeting CD19 hematologic tumors in both preclinical and clinical trials (NCT03085173) (79, 80), and even effective anti-tumor effects in solid tumors targeting B7-H3 (81).